Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR)

Data source

CH-SUR (COVID-19 Hospital Based Surveillance) is a prospective hospital surveillance system for COVID-19 coordinated by the Swiss Federal Office of Public Health (FOPH) and the Institute of Global Health (ISG) of the University of Geneva [11, 12], designed to capture detailed information on COVID-19 hospitalised patients in Switzerland. It includes patients hospitalised for more than 24h and diagnosed with COVID-19 confirmed by a laboratory test (e.g. polymerase chain-reaction test, PCR), plus those confirmed by a serology or with a CT-scan and thorax radiography compatible with COVID-19 diagnosis since November 14^th 2020. To date, 21 Swiss hospitals are participating in that surveillance (including university hospitals and cantonal hospitals), and are representative of the overall COVID-19 situation in Switzerland [9].

For each COVID-19 episode recorded in CH-SUR, various information on demographics, admission, clinical information (including comorbidities, complications, admission to intermediate care unit and/or intensive care unit -hereafter IMCU/ICU- and treatments) and follow-up (death, discharge or transfer) are collected. Further information on CH-SUR can be found elsewhere [11]. Of note, since CH-SUR was setup first for surveillance purposes, in a period of high burden for participating hospitals, priority was given to collection of data on admission and follow-up, to enable timely estimates of numbers regarding new cases and outcomes. Hence, the documentation of additional complementary information (which is relatively time consuming) is optional, and is often provided with some delay compared to the mandatory information on admission and follow-up. At the time of data export, the clinical complementary information was complete for about 86% of recorded episodes.

For that analysis, we included all adult (age ≥ 18 years) patients in CH-SUR diagnosed between February 26st 2020 and May 15th 2021, as recorded by June 21st 2021. Patients diagnosed after May 15^th were excluded to reduce the effect of incomplete cases with yet unknown outcome. Out of the 21 hospitals participating to CH-SUR, one hospital had too incomplete data to be included in our analysis (clinical complementary information provided for less than 50% of episodes), and 6 were paediatric hospitals (hence reporting no adult case), consequently the data we used was collected from only 14 hospitals.

Statistical analysis

We investigated four different time periods in our analyses, corresponding to the different waves of COVID-19 observed in Switzerland, which are defined in Table 1. However, due to the limited time span of the last period and the partial incompleteness of these data, the interpretation of results focus on the comparison between the first and the second wave.The outcome of a COVID-19 episode was either death due to COVID-19, death due to other cause than COVID-19, discharge (including both recovered patients who go home and those discharged -presumably not infectious anymore- to a nursing home) or transfer to a hospital outside the surveillance network. Patients with no outcome documented were assumed to be still in care.

We conducted a survival analysis, for which time-to-event was calculated from the date of the first COVID-19 diagnosis (i.e. date of first sample positive to SARS-CoV-2 infection or date of first clinical diagnosis with imaging) to either the date of outcome or the censoring date. We accounted for competing risks, with death due to COVID-19 being the outcome of interest, and death due to other causes, discharge and transfer being considered as competing risks. Patients still in care were censored at the date of the data export (June 21st 2021) [13].

We calculated crude cumulative incidence functions (CIF) for death, overall and per time period, using the R package mstate [13, 14]. We used univariable and multivariable Fine and Gray models [15] to determine risk factors of mortality, adjusting for sex (male, female), age (as a continuous variable with restricted cubic splines [16]), time period of COVID-19 diagnosis (first wave, intermediate phase, second wave, last period), obesity (no, yes), smoking (no, yes), chronic respiratory disease (no, yes), cardiovascular disease (no, yes), renal disease (no, yes), oncological pathologies (no, yes), dementia (no, yes), immunosuppression (no, yes). We excluded patients with missing age, sex, or outcome date when the outcome was documented. We imputed missing values of all other covariables using multiple imputation by chained equation (R package mice [17]), adding the outcome and time to event to improve the results of the imputation. We ran the model on 20 imputed datasets for each analysis, and combined the estimates with Rubin’s rule [17]. For patients with multiple hospitalisations recorded in CH-SUR, we used the information on comorbidities provided at the first admission. We considered only the outcome of the last hospitalisation, and time-to-event was defined as the time from the date of first COVID-19 diagnosis to the date of the last outcome (or the time of censoring if considered still in care).

In a sensitivity analysis, we recalculated univariable and multivariable Fine and Gray models without multiple imputation, excluding all episodes with incomplete information on any of the adjusted covariables.

Patients on intensive and intermediate care

Similar analyses were conducted for the subgroup of patients who have ever been admitted to intermediate care or ICU (hereafter IMCU/ICU) during their COVID-19 episode(s), with time-to-event being defined as the time from first admission in IMCU/ICU to either the date of outcome or the censoring date. Risk factors of mortality among that IMCU/ICU subgroup were explored using Fine and Gray models as detailed above, adding to the adjusted covariables: use of invasive ventilation during any of IMCU/ICU stays (no, yes), use of non-invasive ventilation during any of the IMCU/ICU stays (no, yes). For sensitivity purposes, we repeated this analysis but included only patients ever admitted to ICU.

Patients and COVID-19 episodes characteristics

As of June 21st 2021, 16,513 COVID-19 episodes were recorded in CH-SUR, 16,030 of which were included in our analysis with 2,320 reported deaths (14.5% of included episodes), 2,084 of which being reported to be due to COVID-19 (13.0% of included episodes).

Characteristics of included episodes, overall and for the first and second waves of COVID-19, are shown in Table 2 and Table 3. The complete table of characteristics of all the included episodes, overall and stratified by time period, can be found in Appendix 1.

Of 2,084 deaths due to COVID-19 recorded in CH-SUR by the date of data export, 434 patients were diagnosed during the first wave, and 1,422 during the second wave. Crude in-hospital COVID-19 mortality ratios were 15.6% for patients diagnosed during the first wave, and 14.0% for those diagnosed during the second wave. Hospitalised COVID-19 patients were slightly older in the second wave (median 73 years, IQR 61 – 82 years) than in the first wave (median 69 years, IQR 55 – 80 years), and the proportion of male patients was slightly higher in the first wave (60.3%) than in the second wave (57.5%). Mild severity score at admission (CURB-65 score) tended to be more frequent in the second wave (21.0% with score 0, 37.8% with score 1, 28.8% with score 2) than in the first wave (30.7% with score 0, 33.7% with score 1, 23.9% with score 2).

Because the clinical complementary information is often entered in the database with some delay, data on comorbidities was slightly less complete for the second compared to the first wave (respectively 3.2% and 0.3% of episodes with missing information on presence of any comorbidity). However, hospitalised patients diagnosed during the second wave were more comorbid than those diagnosed during the first wave (resp. 86.8% and 79.6% of patients who had information on presence or absence of comorbidities available).

The median time from first COVID-19 diagnosis to outcome (or censoring) was 11 days (6 – 21 days) for the first wave, and 13 days (IQR 7 – 21 days) for the second wave. The duration of hospital stay was similar between the first (median of 10 days, IQR 5 – 22 days) and the second waves (median 10 days, IQR 5 - 19 days). Time from diagnosis to first hospital admission was often equal to zero in both waves, meaning that most patients are tested at hospital entry, however it tends to be shorter in the first wave (3^rd quartile 2 days) than in the second wave (3^rd quartile 4 days).

Differences in overall in-hospital COVID-19 mortality by time period

Figure 1 shows cumulative incidence functions of death due to COVID-19 for each time period. Similar figures for the other outcomes (discharge, transfer, death due to other causes) can be found in Appendix 2. For the first wave, about 75% of deaths occurred within 15 days after diagnosis, and the probability of death increased from 5.1% after one week of diagnosis to 10.7% after 2 weeks, 14.1% after 4 weeks and 15.1% after 6 weeks. In contrast, for the second wave, about 67% of deaths occurred within 15 days after diagnosis, and the probability of death increased from 3.6% after one week to 8.4% after 2 weeks, 12.4% after 4 weeks and 13.5% after 6 weeks. This indicates that the probability of death was lower in the second wave than in the first wave, and that death tended to occur later after diagnosis in the second wave compared to the first wave.

• Download figure
• Open in new tab

Figure 1:

Cumulative incidences of death due to COVID-19 in CH-SUR, for the different waves of COVID-19.

Table 4 shows the hazard ratios (HRs) for in-hospital mortality for the different time periods, with 95% confidence intervals (95% CI), from the Fine and Gray models. HRs and 95% CI for all the covariables included in the models can be found in Appendix 3. The overall risk of death was lower for hospitalised patients diagnosed during the second wave compared to those diagnosed during the first wave (HR 0.71, 95% CI 0.69 – 0.73).

Analysis of patients admitted to IMCU/ICU

As of June 21st 2021, 3,437 patients were admitted at least once to IMCU/ICU. For the 3,437 patients, 3,455 episodes were recorded (out of 16,030 included in the main analysis, i.e. 25.1%), 812 in the first wave and 1,993 in the second wave. Overall, for 3,429 of them the time to event variable was available (811 for the first wave, 1,980 for the second wave), with time to event being defined as time from first IMCU/ICU admission to outcome (or censoring). Characteristics of all those episodes, overall and stratified by time period of COVID-19 diagnosis can be found in Appendix 4. The proportion of patients ever admitted to IMCU/ICU was lower in the second wave than in the first wave (Table 3). The time elapsed from COVID-19 diagnosis to first admission into IMCU/ICU was longer in the second wave (median 4 days, IQR 0 – 8 days) than in the first wave (median 2 days, IQR 0 – 5 days). The time from first IMCU/ICU admission to outcome (or census) was similar in the second wave (median 16 days, IQR 9 – 30 days) and in the first wave (median 16 days, IQR 8 – 34 days). Moreover, the proportion of patients who ever went to IMCU/ICU and experienced invasive ventilation was higher in the first wave (53.6%) compared to the second wave (44.7%).

Similarly to all hospitalized patients, IMCU/ICU patients of the second wave were more comorbid than those of the first wave (88.4% versus 82.2%). Crude in-hospital COVID-19 mortality rates among patients who were admitted to IMCU/ICU are 19.0% and 27.1% for patients hospitalised during the first wave, and second wave, respectively.

Cumulative incidence functions for death due to COVID-19 during the different waves, limited to patients ever admitted to IMCU/ICU, are shown in Figure 2. Similar CIFs for the other outcomes (death due to other causes, discharge and transfer) can be found in Appendix 5. During the first wave, about 82% of deaths occurred within 4 weeks after first admission to IMCU/ICU; the probability of death among IMCU/ICU patients increased from 5.8% after one week to 11.2% after 2 weeks, 15.5% after 4 weeks and 17.9% after 6 weeks. During the second wave, about 88% of deaths occurred within 4 weeks after first admission to IMCU/ICU; the probability of death increased from 8.2% after one week to 14.6% after 2 weeks, 23.5% after 4 weeks and 25.9% after 6 weeks. This indicates that the probability of death among IMCU/ICU patients was higher in the second wave than in the first wave, and that death tended to occur earlier after IMCU/ICU admission in the second wave compared to the first wave.

• Download figure
• Open in new tab

Figure 2:

Cumulative incidence functions of death due to COVID-19 for patients admitted to IMCU/ICU, for the different time periods.

HRs associated with time period and use of invasive ventilation from Fine and Gray models are shown in Table 5. HRs and 95% CI for all the covariables included in the models can be found in Appendix 6. The risk of death was higher for patients who ever were admitted to IMCU/ICU during the second wave compared to the first wave (HR 1.49, 95% CI 1.43 – 1.55), and overall patients who underwent invasive ventilation also presented a higher mortality (HR 2.66, 95% CI 2.57 – 2.77), as well as patients who ever underwent non-invasive ventilation (HR 2.62, 95% CI 2.34 – 2.93).

Results from the sensitivity analyses, limited to patients ever admitted to ICU, can be found in Appendix 7, Appendix 8 and Appendix 9. The proportion of patients who ever were admitted to ICU was lower in the second wave than in the first wave (Table 2). During the second wave, compared to the first wave, ICU patients had a longer time from diagnosis to first ICU admission (median 4 days IQR 0 - 8 days, versus median 3 days IQR 0 – 6 days), shorter time from first ICU admission to outcome (median 18 days IQR 10 – 32 days, versus median 23 days IQR 12 - 41 days), a significantly lower use of invasive ventilation (60.7% versus 82.9%), and an increased risk of death (HR 1.39, 95% CI 1.32 – 1.45).